Candriam S.C.A. Glycomimetics Inc Transaction History

Candriam S.C.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 21, 2020	SELL	$4.03 - $6.5 $390,507 - $629,850	-96,900 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$10.6 - $13.12 $249,100 - $308,320	23,500 Added 32.02%	96,900 $1.15 Million
Q1 2019 May 02, 2019	BUY	$9.96 - $13.44 $731,064 - $986,496	73,400 New	73,400 $915,000

28.9M

51K

1.4K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.